

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Kaposi Sarcoma of All Sites

(M-9140)

Note: This scheme cannot be compared to either the Historic Stage or the 1977 Summary Stage schemes.

CS Tumor Size	CS Site-Specific Factor 1 Associated with HIV/AIDS	<p>The following tables are available at the collaborative staging website: Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage</p>
CS Extension	CS Site-Specific Factor 2	
CS Tumor Size/Ext Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Lymph Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam	CS Site-Specific Factor 7	
CS Mets at DX	CS Site-Specific Factor 8	
CS Mets Eval	CS Site-Specific Factor 9	
	CS Site-Specific Factor 10	
	CS Site-Specific Factor 11	
	CS Site-Specific Factor 12	
	CS Site-Specific Factor 13	
	CS Site-Specific Factor 14	
	CS Site-Specific Factor 15	
	CS Site-Specific Factor 16	
	CS Site-Specific Factor 17	
	CS Site-Specific Factor 18	
	CS Site-Specific Factor 19	
	CS Site-Specific Factor 20	
	CS Site-Specific Factor 21	
	CS Site-Specific Factor 22	
	CS Site-Specific Factor 23	
	CS Site-Specific Factor 24	
	CS Site-Specific Factor 25	

Kaposi Sarcoma of All Sites

CS Tumor Size (Revised: 12/30/2009)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable
988	Not applicable: Information not collected for this schema

Kaposi Sarcoma of All Sites

CS Extension (Revised: 09/30/2009)

Code	Description	TNM 7	TNM 6	SS77	SS2000
110	Single lesion: Skin	NA	NA	U	L
120	Single lesion: Mucosa (e.g., oral cavity, anus, rectum, vagina, vulva)	NA	NA	U	L

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
130	Single lesion: Viscera (e.g., pulmonary, gastrointestinal tract, spleen, other)	NA	NA	U	L
210	Multiple lesions: Skin	NA	NA	U	L
220	Multiple lesions: Mucosa (e.g., oral cavity, anus, rectum, vagina, vulva)	NA	NA	U	L
230	Multiple lesions: Viscera (e.g., pulmonary, gastrointestinal tract, spleen, other)	NA	NA	U	L
240	(21) + (22)	NA	NA	U	RE
250	(21) + (23)	NA	NA	U	RE
260	(22) + (23)	NA	NA	U	RE
270	(21) + (22) + (23)	NA	NA	U	D
290	Multiple lesions, NOS	NA	NA	U	U
950	No evidence of primary tumor	NA	NA	U	U
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	NA	U	U

Kaposi Sarcoma of All Sites

CS Tumor Size/Ext Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Kaposi Sarcoma of All Sites

CS Lymph Nodes (Revised: 09/30/2009)

Note: For this site, code ALL lymph node involvement in this field.

Code	Description	TNM 7	TNM 6	SS77	SS2000
000	No lymph node involvement (No clinical adenopathy and either pathologically negative or no pathological statement)	NA	NA	U	NONE

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
100	Clinically enlarged palpable lymph node(s) (adenopathy), and either pathologically negative nodes or no pathological statement	NA	NA	U	RN
200	No clinically enlarged palpable lymph node(s) (adenopathy) but pathologically positive lymph node(s)	NA	NA	U	RN
300	Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive lymph nodes Lymph nodes, NOS	NA	NA	U	RN
999	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NA	NA	U	U

Kaposi Sarcoma of All Sites

CS Lymph Nodes Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Kaposi Sarcoma of All Sites

Reg LN Pos (Revised: 03/30/2009)

Note: Record this field even if there has been preoperative treatment.

Code	Description
00	All nodes examined negative.
01-89	1 - 89 nodes positive (code exact number of nodes positive)
90	90 or more nodes positive
95	Positive aspiration or core biopsy of lymph node(s)
97	Positive nodes - number unspecified
98	No nodes examined
99	Unknown if nodes are positive; not applicable Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Kaposi Sarcoma of All Sites

Reg LN Exam (Revised: 03/02/2009)

Code	Description
00	No nodes examined
01-89	1 - 89 nodes examined (code exact number of regional lymph nodes examined)
90	90 or more nodes examined
95	No regional nodes removed, but aspiration or core biopsy of regional nodes performed
96	Regional lymph node removal documented as sampling and number of nodes unknown/not stated
97	Regional lymph node removal documented as dissection and number of nodes unknown/not stated
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but number unknown
99	Unknown if nodes were examined; not applicable or negative Not documented in patient record

Kaposi Sarcoma of All Sites

CS Mets at DX (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
88	OBSOLETE DATA CONVERTED V0200 See code 98 Not applicable	ERROR	ERROR	ERROR	ERROR
98	Not applicable: Information not collected for this schema	NA	NA	U	U

Kaposi Sarcoma of All Sites

CS Mets Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 1 Associated with HIV/AIDS (Revised: 06/30/2008)

Note: HIV (Human Immunodeficiency Virus) includes types I and II. Older terminology includes HTLV-3 and LAV.

Code	Description
001	Yes/Present
002	No/Not present

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
999	Unknown if present or not Insufficient information Not documented in patient record

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 2 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 3 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 4 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 5 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 6 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 7 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 8 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Kaposi Sarcoma of All Sites

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

(ICD-O-3 M-959-972 EXCEPT 9700/3 and 9701/3)

(ICD-O-3 M-9823, 9827, EXCEPT C42.0, C42.1, C42.4)

CS Tumor Size	CS Site-Specific Factor 1 Associated with HIV/AIDS	The following tables are available at the collaborative staging website: Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage
CS Extension	CS Site-Specific Factor 2 Systemic Symptoms at Diagnosis	
CS Tumor Size/Ext Eval	CS Site-Specific Factor 3 International Prognostic Index (IPI)	
CS Lymph Nodes	CS Site-Specific Factor 4 Follicular Lymphoma Prognostic Index (FLIPI)	
CS Lymph Nodes Eval	CS Site-Specific Factor 5 International Prognostic Score (IPS)	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam	CS Site-Specific Factor 7	
CS Mets at DX	CS Site-Specific Factor 8	
CS Mets Eval	CS Site-Specific Factor 9	
	CS Site-Specific Factor 10	
	CS Site-Specific Factor 11	
	CS Site-Specific Factor 12	
	CS Site-Specific Factor 13	
	CS Site-Specific Factor 14	
	CS Site-Specific Factor 15	
	CS Site-Specific Factor 16	
	CS Site-Specific Factor 17	
	CS Site-Specific Factor 18	
	CS Site-Specific Factor 19	
	CS Site-Specific Factor 20	
	CS Site-Specific Factor 21	
	CS Site-Specific Factor 22	
	CS Site-Specific Factor 23	
	CS Site-Specific Factor 24	
	CS Site-Specific Factor 25	

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Tumor Size (Revised: 12/30/2009)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable
988	Not applicable: Information not collected for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Extension (Revised: 01/08/2010)

Note 1: For lymphoma an E lesion is defined as disease that involves extralymphatic site(s). Extralymphatic means other than lymph nodes and other lymphatic structures. These lymphatic structures include spleen (see note 2), thymus gland (C37.9), Waldeyer's ring (tonsils) (C02.4, C09.0-C09.9, C11.1, C14.2), Peyer's patches (ileum) (C17.2) and lymphoid nodules in the appendix (C18.1). Any lymphatic structure (other than spleen) is to be coded the same as a lymph node region (codes 100, 200, 300).

Note 2: While Spleen is considered a lymphatic structure, it is coded separately (see codes 120, 220, 230, 320, 330). S equals Spleen involvement.

Note 3: If there is no mention of lymphatic or extralymphatic involvement but several diagnostic procedures were done, including laparotomy, interpret as no involvement.

Note 4: Involvement of adjacent soft tissue does not alter the classification.

Code	Description	TNM 7	TNM 6	SS77	SS2000
100	Involvement of a single lymph node region Stated as Stage I	^	*	L	L
110	Localized involvement of a single extralymphatic organ/ site in the absence of any lymph node involvement Multifocal involvement of one extralymphatic organ/site Stated as Stage IE	^	*	L	L
120	Involvement of spleen only Staged as Stage IS	^	*	L	L
200	Involvement of two or more lymph node regions on the SAME side of the diaphragm Staged as Stage II	^	*	RNOS	RNOS
210	Localized involvement of a single extralymphatic organ/site WITH involvement of its regional lymph node(s) WITH or WITHOUT involvement of other lymph node(s) on the SAME side of the diaphragm Direct extension to adjacent organs or tissues Staged as Stage IIE	^	*	RNOS	RNOS
220	Involvement of spleen PLUS lymph node(s) BELOW the diaphragm Stated as Stage IIS	^	*	RNOS	RNOS
230	Involvement of spleen PLUS involvement of a single extralymphatic organ/site BELOW the diaphragm WITH/WITHOUT involvement of lymph node(s) BELOW the diaphragm Staged as Stage IIES	^	*	RNOS	RNOS
300	Involvement of lymph node regions on BOTH sides of the diaphragm Staged as Stage III	^	*	D	D

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
310	Involvement of an extralymphatic organ/site PLUS involvement of lymph node(s) on the OPPOSITE side of the diaphragm Staged as Stage IIIE	^	*	D	D
320	Involvement of the spleen PLUS lymph node(s) ABOVE the diaphragm Involvement of spleen PLUS lymph nodes on both sides of the diaphragm. Staged as Stage IIIS	^	*	D	D
330	(31) + (32) OR Involvement of the spleen PLUS a single extralymphatic site ABOVE the diaphragm WITH/WITHOUT involvement of lymph node(s) Involvement of the spleen PLUS involvement of lymph node region(s) ABOVE the diaphragm PLUS involvement of a single extralymphatic organ/site on either side of the diaphragm Staged as Stage IIIES	^	*	D	D
800	Diffuse or disseminated (multifocal) involvement of ONE OR MORE extralymphatic organ(s)/site(s) WITH OR WITHOUT associated lymph node involvement Multifocal involvement of MORE THAN ONE extralymphatic organ/site Involvement of isolated extralymphatic organ in absence of involvement of adjacent lymph nodes, but in conjunction with disease in distant sites Metastasis/involvement: Bone marrow Liver Nodular involvement of lung(s) Staged as Stage IV	^	*	D	D
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	^	*	U	U

* AJCC stage group for this site is derived directly from the extension code and SSF#2, as shown in the AJCC TNM 6th edition Stage table. The AJCC Stages Groups I-IV are subdivided into A and B based on presence or absence of symptoms as shown in SSF#2.

^ AJCC stage group for this site is derived directly from the extension code and SSF#2, as shown in the AJCC TNM 7th edition Stage table. The AJCC Stages Groups I-IV are subdivided into A and B based on presence or absence of symptoms as shown in SSF#2.

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Tumor Size/Ext Eval (Revised: 06/06/2009)

Note: According to AJCC, "The use of the term pathologic staging is reserved for patients who undergo staging laparotomy with an explicit intent to assess the presence of abdominal disease or to define histologic microscopic disease extent in the abdomen. Staging laparotomy and pathological staging have been essentially abandoned as useful procedures." (7th ed., page) Therefore, Collaborative Staging uses a modified evaluation scheme for lymphomas, and it applies to the CS Tumor Size/Ext-Eval field only. The other Eval fields are coded as "not applicable" for this schema.

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging: No staging laparotomy done. No autopsy evidence used	c
2	Meets criteria for AJCC pathologic staging: No surgical resection done, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy)	p
3	Meets criteria for AJCC pathologic staging: Staging laparotomy done	p
8	Meets criteria for autopsy (a) staging: Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy).	a
9	Unknown if staging laparotomy done Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Lymph Nodes (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable	ERROR	ERROR	ERROR	ERROR
988	Not applicable: Information not collected for this schema	NA	NA	U	U

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Lymph Nodes Eval (Revised: 11/12/2009)

Code	Description	Staging Basis
9	Not applicable for this site.	

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

Reg LN Pos (Revised: 06/30/2008)

Code	Description
99	Not applicable

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

Reg LN Exam (Revised: 06/30/2008)

Code	Description
99	Not applicable

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Mets at DX (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
88	OBSOLETE DATA CONVERTED V0200 See code 98 Not applicable	ERROR	ERROR	ERROR	ERROR
98	Not applicable: Information not collected for this schema	NA	NA	U	U

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Mets Eval (Revised: 11/12/2009)

Code	Description	Staging Basis
9	Not applicable for this site.	

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 1 Associated with HIV/AIDS (Revised: 07/20/2009)

Note: HIV (Human Immunodeficiency Virus) includes types I and II. Older terminology includes HTLV-3 and LAV.

Code	Description
001	Yes/Present
002	No/Not present

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
999	Unknown if present or not Insufficient information Not documented in patient record

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 2 Systemic Symptoms at Diagnosis (Revised: 11/12/2009)

Note 1: Each stage should be classified as either A or B according to the absence or presence of defined constitutional symptoms, such as: 1. Fevers: Unexplained fever with temperature above 38 degrees C; 2. Night sweats: Drenching sweats that require change of bedclothes; 3. Weight loss: Unexplained weight loss of more than 10% of the usual body weight in the 6 months prior to diagnosis.

Note 2: Pruritus alone does not qualify for B classification, nor does alcohol intolerance, fatigue, or a short, febrile illness associated with suspected infections.

Note 3: Assign code 000 if the History and Physical, progress notes or consultations make no mention of "B" symptoms.

Code	Description	Modifier
000	No B symptoms (Asymptomatic)	A
010	Any B symptoms: Night sweats Unexplained fever (above 38 degrees C) Unexplained weight loss (generally greater than 10% of body weight in the six months before admission) B symptoms, NOS	B
020	Pruritis (if recurrent and unexplained)	A
030	(010) + (020)	B
999	Unknown if symptoms; insufficient information Not documented in patient record	BLANK

The "A" or "B" is appended to the stage I-IV as determined in the data item CS Site-Specific Factor 2, Systemic Symptoms at Diagnosis.

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 3 International Prognostic Index (IPI) (Revised: 11/04/2009)

Note 1: The IPI has been developed for lymphomas and predicts outcome based on the following adverse factors:
Age more than 60 years Stage III or IV Number of extranodal sites involved more than 1 Patient's performance status (ECOG) more than 2 Serum LDH level abnormal

Note 2: Record the IPI as stated in the medical record. Do not calculate points or assign risk. Only record points or risk if a physician has documented them. Use points over risk if both are available.

Note 3: There are now three indices/score associated with Lymphoma: The International Prognostic Index (IPI, SSF3); the Follicular Lymphoma International Prognostic Index (FLIPI, SSF4) and the International Prognostic Score (for Hodgkin lymphomas, SSF5.) Physicians may use these indices/scores interchangeably. If the point value and the index/score is documented, code the appropriate SSF and the other two SSF's as 999. If a point value of 5 or less is documented, but there is no documentation for which index/score was used, code 999 for all three SSF's. If the point value is 6 or 7, code SSF5 (IPS).

Code	Description
000	0 points
001	1 point
002	2 points
003	3 points
004	4 points
005	5 points
990	Stated as low risk (0-1 points)
991	Stated as low intermediate risk (2 points)
992	Stated as intermediate risk (3 points)
993	Stated as high risk (4-5 points)
999	Unknown Insufficient information Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 4 Follicular Lymphoma Prognostic Index (FLIPI) (Revised: 12/31/2009)

Note 1: The FLIPI has been developed for follicular lymphomas and predicts outcome based on the following adverse factors: Age more than 60 years Stage III or IV Number of extranodal sites involved more than 4 Serum LDH level abnormal Serum hemoglobin concentration less than 12

Note 2: Record the FLIPI as documented in the medical record. Do not calculate points or assign risk. Only record points or risk if a physician has documented them. Use points over risk if both are available.

Note 3: There are now three indices/score associated with Lymphoma: The International Prognostic Index (IPI, SSF3); the Follicular Lymphoma International Prognostic Index (FLIPI, SSF4) and the International Prognostic Score (for Hodgkin lymphomas, SSF5.) Physicians may use these indices/scores interchangeably. If the point value and the index/score is documented, code the appropriate SSF and the other two SSF's as 999. If a point value of 5 or less is documented, but there is no documentation for which index/score was used, code 999 for all three SSF's. If the point value is 6 or 7, code SSF5 (IPS).

Code	Description
000	0 points
001	1 point
002	2 points
003	3 points
004	4 points
005	5 points
888	OBSOLETE DATA CONVERTED V0200 See code 988: Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
990	Stated as low risk (0-1 points)
991	Stated as intermediate risk (2 points)
992	Stated as high risk (3-5 points)
999	Unknown Insufficient information Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 5 International Prognostic Score (IPS) (Revised: 12/31/2009)

Note 1: The IPS has been developed for Hodgkin lymphoma and predicts outcome based on the following adverse factors: Male sex Age more than or equal to 45 years Stage IV disease Serum albumin less than 4g/dL Hemoglobin concentration less than 10.5 g/dl White blood cell count more than or equal to 15,000 mm Lymphocytopenia less than 600/mm (8%)

Note 2: Record the IPS score as documented in the medical record. Do not calculate points. Only record points if a physician has documented them.

Note 3: There are now three indices/score associated with Lymphoma: The International Prognostic Index (IPI, SSF3); the Follicular Lymphoma International Prognostic Index (FLIPI, SSF4) and the International Prognostic Score (for Hodgkin lymphomas, SSF5.) Physicians may use these indices/scores interchangeably. If the point value and the index/score is documented, code the appropriate SSF and the other two SSF's as 999. If a point value of 5 or less is documented, but there is no documentation for which index/score was used, code 999 for all three SSF's. If the point value is 6 or 7, code SSF5 (IPS).

Code	Description
000	0 points
001	1 point
002	2 points
003	3 points
004	4 points
005	5 points
006	6 points
007	7 points
888	OBSOLETE DATA CONVERTED V0200 See code 988: Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
999	Unknown Insufficient information Not documented in patient record

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 6 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 7 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 8 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hodgkin and Non-Hodgkin Lymphomas of All Sites (excl. Mycosis Fungoides and Sezary Disease)

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

(M-9731-9734, 9740-9742, 9750-9758, 9760-9762, 9764-9769, 9800-9801, 9805-9809, 9811-9818, 9820, 9823 [C420, C421, or C424 ONLY], 9826, 9827 [C420, C421, or C424 ONLY], 9831-9837, 9840, 9860-9861, 9863, 9865-9867, 9869-9876, 9891, 9895-9898, 9910, 9920, 9930-9931, 9940, 9945-9946, 9948, 9950, 9960-9967, 9970, 9971, 9975, 9980, 9982-9987, 9989, 9991-9992. See site exceptions below.

Schema includes only preferred terms from ICD-O-3.

9731 Plasmacytoma, NOS [except C441, C690, C695-C696]

9732 Multiple myeloma [except C441, C690, C695-C696]

9733 Plasma cell leukemia [except C441, C690, C695-C696]

9734 Plasmacytoma, extramedullary [except C441, C690, C695-C696]

9740 Mast cell sarcoma

9741 Malignant mastocytosis

9742 Mast cell leukemia

9750 Malignant histiocytosis

9752 Langerhans cell histiocytosis, unifocal* (see new reportable code 9751/3)

9753 Langerhans cell histiocytosis, multifocal* (see new reportable code 9751/3)

9754 Langerhans cell histiocytosis disseminated

9755 Histiocytic sarcoma

9756 Langerhans cell sarcoma

9757 Interdigitating dendritic cell sarcoma

9758 Follicular dendritic cell sarcoma

9760 Immunoproliferative disease, NOS

9761 Waldenstrom macroglobulinemia

9762 Heavy chain disease, NOS

9764 Immunoproliferative small intestinal disease

9765 Monoclonal gammopathy of undetermined significance*

9766 Angiocentric immunoproliferative lesion*

9767 Angioimmunoblastic lymphadenopathy*

9768 T-gamma lymphoproliferative disease*

9769 Immunoglobulin deposition disease*

9800 Leukemia, NOS

9801 Acute leukemia, NOS

9805 Acute biphenotypic leukemia

9820 Lymphoid leukemia, NOS [except C441, C690, C695-C696]

9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma [C420, C421, or C424 ONLY]

9826 Burkitt cell leukemia leukemia [except C441, C690, C695-C696]

9827 Adult T-cell leukemia/lymphoma (HTLV-1 positive)[C420, C421, or C424 ONLY]

9832 Prolymphocytic leukemia, NOS [except C441, C690, C695-C696]

9833 Prolymphocytic leukemia, B-cell type [except C441, C690, C695-C696]

9834 Prolymphocytic leukemia, T-cell type [except C441, C690, C695-C696]

9835 Precursor cell lymphoblastic leukemia, NOS [except C441, C690, C695-C696]

9836 Precursor B-cell lymphoblastic leukemia [except C441, C690, C695-C696]

9837 Precursor T-cell lymphoblastic leukemia [see 9837 below, new definition]

9840 Acute myeloid leukemia, M6 type

9860 Myeloid leukemia, NOS

9861 Acute myeloid leukemia, NOS

9863 Chronic myeloid leukemia

9866 Acute promyelocytic leukemia

9867 Acute myelomonocytic leukemia

9870 Acute basophilic leukemia

9871 Acute myeloid leukemia with abnormal marrow, eosinophils

9872 Acute myeloid leukemia, minimal differentiation

9873 Acute myeloid leukemia without maturation

9874 Acute myeloid leukemia with maturation

9875 Chronic myelogenous leukemia, BCR/ABL positive

Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

9876 Atypical chronic myeloid leukemia BCR/ABL negative
9891 Acute monocytic leukemia
9895 Acute myeloid leukemia with multilineage dysplasia
9896 Acute myeloid leukemia, t(8;21)(q22;q22)
9897 Acute myeloid leukemia, 11q23 abnormalities
9910 Acute megakaryoblastic leukemia
9920 Therapy-related acute myeloid leukemia, NOS
9930 Myeloid sarcoma
9931 Acute panmyelosis with myelofibrosis
9940 Hairy cell leukemia
9945 Chronic myelomonocytic leukemia, NOS
9946 Juvenile myelomonocytic leukemia
9948 Aggressive NK-cell leukemia
9950 Polycythemia (rubra) vera
9960 Chronic myeloproliferative disease, NOS
9961 Myelosclerosis with myeloid metaplasia
9962 Essential thrombocythemia
9963 Chronic neutrophilic leukemia
9964 Hypereosinophilic syndrome
9970 Lymphoproliferative disorder, NOS*
9975 Myeloproliferative disease, NOS*
9980 Refractory anemia, NOS
9982 Refractory anemia with sideroblasts
9983 Refractory anemia with excess blasts
9984 Refractory anemia with excess blasts in transformation
9985 Refractory cytopenia with multilineage dysplasia
9986 Myelodysplastic syndrome with 5q deletion (5q-) syndrome
9987 Therapy-related myelodysplastic syndrome, NOS
9989 Myelodysplastic syndrome, NOS

The following ICD-O codes were added to the reportable list for Hematopoietic diseases. These are from the "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 3rd edition" publication, which was released in 2008. These new codes have been incorporated into the new Hematopoietic and Lymphoid Neoplasm MP/H rules. Use these only for cases diagnosed on January 1, 2010 and forward.

9751 Langerhans cell histiocytosis, NOS
9806 Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1
9807 Mixed phenotype acute leukemia with t(v;11q23); MLL, rearranged
9808 Mixed phenotype acute leukemia, B/myeloid, NOS
9809 Mixed phenotype acute leukemia, T/myeloid, NOS
9811 B lymphoblastic leukemia/lymphoma, NOS [C420, C421, or C424 ONLY]
9812 B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 [C420, C421, or C424 ONLY]
9813 B lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged [C420, C421, or C424 ONLY]
9814 B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) [C420, C421, or C424 ONLY]
9815 B lymphoblastic/lymphoma with hyperdiploidy [C420, C421, or C424 ONLY]
9816 B lymphoblastic/lymphoma with hypodiploidy (hypodiploid ALL) [C420, C421, or C424 ONLY]
9817 B lymphoblastic/lymphoma with t(5;14)(q31;q32); IL3-IGH [C420, C421, or C424 ONLY]
9818 B lymphoblastic/lymphoma with t(1;19)(q23;p13.3); E2A PBX1 (TCF3 PBX1) [C420, C421, or C424 ONLY]
9831 T-cell large granular lymphocytic leukemia [except C441, C690, C695-C696]
9837 T lymphoblastic leukemia/lymphoma [C420, C421, or C424 ONLY]
9865 Acute myeloid leukemia with t(6;9)([23;q34) DEK-NUP214
9869 Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26;2); RPN1EVI1
9898 Myeloid leukemia associated with Down Syndrome
9911 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
9965 Myeloid and lymphoid neoplasms with PDGFRB rearrangement
9966 Myeloid neoplasm with PDGFRB arrangement
9967 Myeloid and lymphoid neoplasm with FGFR1 abnormalities
9971 Polymorphic PTLD

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

9975 Myeloproliferative neoplasm, unclassifiable

9991 Refractory neutropenia

9992 Refractory thrombocytopenia

*Usually considered of uncertain/borderline behavior

Note: AJCC does not define TNM staging for this site.

CS Tumor Size	CS Site-Specific Factor 1 JAK-2 (also known as Janus Kinase 2 and JAK 2 Exon 12)	The following tables are available at the collaborative staging website: Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage
CS Extension	CS Site-Specific Factor 2	
CS Tumor Size/Ext Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Lymph Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam	CS Site-Specific Factor 7	
CS Mets at DX	CS Site-Specific Factor 8	
CS Mets Eval	CS Site-Specific Factor 9	
	CS Site-Specific Factor 10	
	CS Site-Specific Factor 11	
	CS Site-Specific Factor 12	
	CS Site-Specific Factor 13	
	CS Site-Specific Factor 14	
	CS Site-Specific Factor 15	
	CS Site-Specific Factor 16	
	CS Site-Specific Factor 17	
	CS Site-Specific Factor 18	
	CS Site-Specific Factor 19	
	CS Site-Specific Factor 20	
	CS Site-Specific Factor 21	
	CS Site-Specific Factor 22	
	CS Site-Specific Factor 23	
	CS Site-Specific Factor 24	
	CS Site-Specific Factor 25	

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Tumor Size (Revised: 12/30/2009)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable
988	Not applicable: Information not collected for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Extension (Revised: 09/30/2009)

Code	Description	TNM 7	TNM 6	SS77	SS2000
100	Localized disease: (single/solitary/unifocal/isolated/mono-ostotic) may be coded for: Plasmacytoma, NOS (M-9731/3)(solitary myeloma) Plasmacytoma, extramedullary (M-9734/3) (not occurring in bone) Mast cell sarcoma (M-9740) Malignant histiocytosis (M-9750) Histiocytic sarcoma (M-9755) Langerhans cell sarcoma (M-9756) Dendritic cell sarcoma (M-9757, M-9758) Myeloid sarcoma (M-9930) Langerhans cell histiocytosis (M-9751/3)	NA	NA	L	L
800	Systemic disease (poly-ostotic): All histologies including those in 100	NA	NA	D	D
999	Unknown	NA	NA	D	D

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Tumor Size/Ext Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Lymph Nodes (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable	ERROR	ERROR	ERROR	ERROR
988	Not applicable: Information not collected for this schema	NA	NA	U	U

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Lymph Nodes Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

Reg LN Pos (Revised: 06/30/2008)

Code	Description
99	Not applicable

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

Reg LN Exam (Revised: 06/30/2008)

Code	Description
99	Not applicable

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Mets at DX (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
88	OBSOLETE DATA CONVERTED V0200 See code 98 Not applicable	ERROR	ERROR	ERROR	ERROR
98	Not applicable: Information not collected for this schema	NA	NA	U	U

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Mets Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 1 JAK-2 (also known as Janus Kinase 2 and JAK 2 Exon 12) (Revised: 12/30/2009)

Note 1: JAK2 is a gene mutation that increases susceptibility to several Myeloproliferative neoplasms (MPNs). Testing for the JAK2 mutation is done on whole blood. Nearly all people with polycythemia vera and about half of those with essential thrombocythemia and primary myelofibrosis have the mutation. When JAK2 is positive the MPN is definitely reportable, however JAK2 itself does not specify which MPN is present. Other diagnostic tests are required to determine the specific histology.

Note 2: JAK 2 is used primarily for the following histologies: Polycythemia Vera, Essential Thrombocytopenia and Primary Myelofibrosis. Its usage continues to increase and may be used for other histologies in the future. Record JAK-2 for any Heme-Retic disease even if it is not one of the histologies noted.

Note 3: If JAK-2 test result is positive, NOS, use code 850.

Code	Description
000	JAK-2 test result stated as negative
010	JAK2 test performed, positive for mutation V617F in exon 14
020	JAK2 test performed, positive for mutation of exon 12
800	JAK2 test performed, positive for other specified mutation
810	JAK2 test performed, positive for more than one mutation
850	JAK2 test performed, positive NOS; specific mutation(s) not stated
888	OBSOLETE DATA CONVERTED V0200 See code 988: Not applicable for this schema
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done
999	Unknown Insufficient information Not documented in patient record

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 2 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 3 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 4 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 5 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 6 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 7 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 8 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative Neoplasms

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

**Hematopoietic, Reticuloendothelial, Immunoproliferative, and Myeloproliferative
Neoplasms**

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Sites, Unknown Primary Site

C42.0-C42.4, C76.0-C76.5, C76.7-C76.8, C77.0-C77.5, C77.8-C77.9, C80.9

- C42.0 Blood
- C42.1 Bone marrow
- C42.2 Spleen
- C42.3 Reticuloendothelial system, NOS
- C42.4 Hematopoietic system, NOS
- C76.0 Head, face or neck, NOS
- C76.1 Thorax, NOS
- C76.2 Abdomen, NOS
- C76.3 Pelvis, NOS
- C76.4 Upper limb, NOS
- C76.5 Lower limb, NOS
- C76.7 Other ill-defined sites
- C76.8 Overlapping lesion of ill-defined sites
- C77.0 Lymph nodes of head, face and neck
- C77.1 Lymph nodes of intrathoracic
- C77.2 Lymph nodes of intra-abdominal
- C77.3 Lymph nodes of axilla or arm
- C77.4 Lymph nodes of inguinal region or leg
- C77.5 Lymph nodes of pelvis
- C77.8 Lymph nodes of multiple regions
- C77.9 Lymph nodes, NOS
- C80.9 Unknown primary site

Note 1: AJCC does not define TNM staging for this site.

Note 2: C42._ and C77._, Other than hematopoietic, reticuloendothelial, immunoproliferative and myeloproliferative neoplasms, Hodgkin and non-Hodgkin Lymphomas, and Kaposi sarcoma.

<ul style="list-style-type: none"> CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval 	<ul style="list-style-type: none"> CS Site-Specific Factor 1 CS Site-Specific Factor 2 CS Site-Specific Factor 3 CS Site-Specific Factor 4 CS Site-Specific Factor 5 CS Site-Specific Factor 6 CS Site-Specific Factor 7 CS Site-Specific Factor 8 CS Site-Specific Factor 9 CS Site-Specific Factor 10 CS Site-Specific Factor 11 CS Site-Specific Factor 12 CS Site-Specific Factor 13 CS Site-Specific Factor 14 CS Site-Specific Factor 15 CS Site-Specific Factor 16 CS Site-Specific Factor 17 CS Site-Specific Factor 18 CS Site-Specific Factor 19 CS Site-Specific Factor 20 CS Site-Specific Factor 21 CS Site-Specific Factor 22 CS Site-Specific Factor 23 CS Site-Specific Factor 24 CS Site-Specific Factor 25 	<p>The following tables are available at the collaborative staging website:</p> <ul style="list-style-type: none"> Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage
--	---	--

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Sites, Unknown Primary Site

CS Tumor Size (Revised: 02/03/2010)

Code	Description
000	No mass/tumor found
001-988	001 - 988 millimeters (code exact size in millimeters)
989	989 millimeters or larger
990	Microscopic focus or foci only and no size of focus given
991	Described as "less than 1 cm"
992	Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm"
993	Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm"
994	Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"
995	Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"
999	Unknown; size not stated Not documented in patient record

Other and Ill-Defined Sites, Unknown Primary Site

CS Extension (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable	ERROR	ERROR	ERROR	ERROR
988	Not applicable: Information not collected for this schema	NA	NA	U	U

Other and Ill-Defined Sites, Unknown Primary Site

CS Tumor Size/Ext Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Sites, Unknown Primary Site

CS Lymph Nodes (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable	ERROR	ERROR	ERROR	ERROR
988	Not applicable: Information not collected for this schema	NA	NA	U	U

Other and Ill-Defined Sites, Unknown Primary Site

CS Lymph Nodes Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Other and Ill-Defined Sites, Unknown Primary Site

Reg LN Pos (Revised: 06/30/2008)

Code	Description
99	Not applicable

Other and Ill-Defined Sites, Unknown Primary Site

Reg LN Exam (Revised: 06/30/2008)

Code	Description
99	Not applicable

Other and Ill-Defined Sites, Unknown Primary Site

CS Mets at DX (Revised: 01/13/2010)

Code	Description	TNM 7	TNM 6	SS77	SS2000
88	OBSOLETE DATA CONVERTED V0200 See code 98 Not applicable	ERROR	ERROR	ERROR	ERROR
98	Not applicable: Information not collected for this schema	NA	NA	U	U

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Sites, Unknown Primary Site

CS Mets Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 1 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 2 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 3 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 4 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 5 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 6 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 7 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 8 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Sites, Unknown Primary Site

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema